Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.70 |
| ▸ | HTT | P42858 | 1/20 | 0.70 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.70 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.49 |
| ▸ | CDK1 | P06493 | 1/20 | 0.49 |
| ▸ | CDK4 | P11802 | 1/20 | 0.49 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.49 |
| ▸ | CCND1 | P24385 | 1/20 | 0.49 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1435897 | 1.00 | POLB (0.70) | POLBHTTNPSR1MAOBCCNB2 | |
| SCHEMBL1435898 | 1.00 | POLB (0.70) | POLBHTTNPSR1MAOBCCNB2 | |
| SCHEMBL1435494 | 0.85 | POLB (0.70) | POLBHTTNPSR1MAOB | |
| SCHEMBL1435495 | 0.85 | POLB (0.70) | POLBHTTNPSR1MAOB | |
| SCHEMBL1435493 | 0.85 | POLB (0.70) | POLBHTTNPSR1MAOB | |
| SCHEMBL1435580 | 0.83 | POLB (0.63) | POLBHTTNPSR1MAOB | |
| SCHEMBL1435584 | 0.83 | POLB (0.63) | POLBHTTNPSR1MAOB | |
| SCHEMBL1435581 | 0.83 | POLB (0.63) | POLBHTTNPSR1MAOB | |
| Cinnamaldehyde Thiosemicarbazone SCHEMBL1435430 | 0.83 | POLB (1.00) | POLBHTTNPSR1 | |
| Cinnamaldehyde Thiosemicarbazone SCHEMBL1435428 | 0.83 | POLB (1.00) | POLBHTTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1898908-B1 | NOVEL CHEMICAL COMPOUNDS AND THE USES THEREOF AS A MEDICAMENT | TROPHOS (FR) | 2011-03-30 | — | — | EP | disclosed |
| US-20090203747-A1 | NOVEL CHEMICAL COMPOUNDS AND THE USES THEREOF AS A MEDICINE | TROPHOS PARC SCIENTIFIQUE LUMINY (FR) | 2009-08-13 | — | — | US | disclosed |
| EP-1898908-A2 | NOVEL CHEMICAL COMPOUNDS AND THE USES THEREOF AS A MEDICAMENT | Trophos (FR) | 2008-03-19 | — | — | EP | disclosed |
| WO-2007003767-A2 | NOVEL CHEMICAL COMPOUNDS AND THE USES THEREOF AS A MEDICINE | TROPHOS (FR) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203747-A1 | NOVEL CHEMICAL COMPOUNDS AND THE USES THEREOF AS A MEDICINE | NLN, NQO1, APP | POLB 4234/4885HTT 7/4885NPSR1 696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.